Repare Therapeutics Inc (RPTX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Repare Therapeutics Inc. has been notified by Roche that their collaborative licensing agreement for the development and commercialization of certain ATR inhibitors, including camonsertib, will be terminated without cause, effective May 7, 2024. Despite this, Repare will regain all rights to these products and is set to receive a $40 million milestone payment from Roche. The company confirmed this update through a press release, marking the end of their material relationship with Roche post-termination date.
For further insights into RPTX stock, check out TipRanks’ Stock Analysis page.